Economic evaluation and decision making: reimbursing trastuzumab in early-stage breast cancer.
Simoens
Steven
S
Research Centre for Pharmaceutical Care and Pharmacoeconomics, Katholieke Universiteit Leuven, Leuven, Belgium. steven.simoens@pharm.kuleuven.be
D000911:Antibodies, Monoclonal / Q000191:economics / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000191:economics / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D003362:Cost-Benefit Analysis; D003657:Decision Making; D006801:Humans; D009367:Neoplasm Staging; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis; D012051:Reimbursement Mechanisms / Q000191:economics*; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab